Senseonics

Senseonics Holdings, Inc. is a commercial-stage medical device company with a mission to revolutionize diabetes care via its long-term, implantable CGM platform. Its flagship Eversense system, approved for 180-day wear in the US and 365-day wear in Europe, represents a significant technological differentiation in a market dominated by short-term, transcutaneous sensors. The company's strategy hinges on leveraging its proprietary fluorescent sensor technology and a global commercialization partnership with Ascensia Diabetes Care to capture market share in the multi-billion-dollar CGM landscape.

A proprietary fluorescent-based glucose sensing platform utilizing a long-term implantable sensor, a removable smart transmitter, and a mobile app for continuous glucose monitoring.

Senseonics competes in the CGM market against dominant players Dexcom (real-time CGM) and Abbott (flash glucose monitoring), which have greater scale, brand recognition, and direct-to-consumer reach. Senseonics' strategy is not head-on competition but differentiation through its unique long-term, implantable form factor and clinician-involved model, targeting a specific patient niche.